SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?
Kardiologia Polska · 2024
DOI: 10.33963/v.phj.98860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kardiologia Polska, 2024. Verfasst von Davide Capodanno und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy. dcapodanno@un…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Percutaneous Coronary Intervention, Acute Kidney Injury, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy. dcapodanno@unict.it.
- Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
Zitieren
APA
Capodanno, D., & Finocchiaro, S. (2024). SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?. Kardiologia Polska. https://doi.org/10.33963/v.phj.98860
Vancouver
Capodanno D, Finocchiaro S. SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?. Kardiologia Polska. 2024. doi:10.33963/v.phj.98860
BibTeX
@article{Capodanno2024,
author = {Capodanno, Davide and Finocchiaro, Simone},
title = {SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?},
journal = {Kardiologia Polska},
year = {2024},
doi = {10.33963/v.phj.98860}
}
EUVIMED